INIS
patients
100%
comparative evaluations
55%
receptors
54%
antibodies
47%
risks
47%
drugs
44%
plasma
42%
anticoagulants
40%
evaluation
40%
concentration
38%
doses
35%
reviews
35%
data
31%
performance
29%
sensitivity
29%
thrombin
29%
inflammation
28%
proteins
28%
covid-19
28%
humans
28%
laboratories
27%
diseases
27%
inhibition
26%
levels
23%
synthesis
23%
aggregation
21%
in vitro
20%
assessments
20%
monitoring
20%
vaccines
19%
thrombosis
19%
arachidonic acid
19%
design
18%
heparin
18%
administration
17%
tyrosine
17%
kinases
17%
detection
16%
applications
15%
urea
15%
values
14%
coronaviruses
14%
validation
13%
production
13%
tissues
13%
prostaglandins
13%
rats
13%
management
12%
carbonic anhydrase
12%
recommendations
12%
Pharmacology, Toxicology and Pharmaceutical Science
Anticoagulant Agent
16%
Dabigatran
14%
Thromboxane Receptor
13%
Thromboxane Synthase Inhibitor
13%
Thrombin
13%
Direct Oral Anticoagulant
12%
Thromboxane A2 Receptor Blocking Agent
11%
Arachidonic Acid
10%
Nanomaterial
9%
Rivaroxaban
9%
Thromboxane
9%
Heparin
9%
Dabigatran Etexilate
9%
Thromboxane Receptor Blocking Agent
8%
Procoagulant
8%
Atrial Fibrillation
8%
Thromboembolism
7%
Thromboxane A2
7%
Inflammation
7%
Antivitamin K
7%
Blood Stasis
7%
Activated Protein C Resistance
6%
SARS Coronavirus
6%
Chronic Myeloid Leukemia
6%
Protein Tyrosine Kinase Inhibitor
6%
Vaccination Policy
6%
Neutralizing Antibody
6%
Clinical Study
6%
Carbonate Dehydratase
6%
Apixaban
5%
Oral Contraceptive Agent
5%
Prothrombin
5%
Thromboplastin
5%
COX-2 Inhibitor
5%
Venous Thromboembolism
5%
Bleeding
5%
Thromboxane Synthase
5%
COVID-19 Vaccine
5%
